Current Status of Adjuvant Therapy for Colorectal Cancer
|
|
- Ethelbert Poole
- 6 years ago
- Views:
Transcription
1 Review Article [1] May 01, 2004 By Michael J. O connell, MD [2] Adjuvant therapy with chemotherapy and/or radiation therapy in addition to surgery improves outcome for patients with high-risk carcinomas of the colon or rectum. For colon cancer, fluorouracil (5-FU) combined with leucovorin is a current standard of care that improves long-term survival. A recent European trial (MOSAIC) has documented significant improvement in 3-year disease-free survival when oxaliplatin (Eloxatin) was added to infusional 5-FU and leucovorin in the FOLFOX regimen. Two US cooperative group trials will evaluate the addition of antiangiogenesis therapy with bevacizumab (Avastin) to chemotherapy. A third trial will evaluate FOLFOX, irinotecan (Camptosar) combined with infusional 5-FU and leucovorin (FOLFIRI), and the sequential use of FOLFOX followed by FOLFIRI. In rectal cancer, postoperative 5-FU based chemotherapy combined with irradiation can improve both local tumor control and survival. The German Rectal Cancer Group has recently reported that preoperative combined-modality therapy is less toxic and more effective in preventing local tumor relapse compared to similar treatment given postoperatively. A coordinated pair of cooperative group clinical trials will evaluate oral capecitabine (Xeloda) as a radiation enhancer in the preoperative setting, and the FOLFOX and FOLFIRI regimens compared to 5-FU and leucovorin following surgery. Predictive and prognostic molecular markers will be studied in these new adjuvant therapy clinical trials for both colon and rectal cancer with the goal of developing future regimens tailored to individual patients. There has been a recent and dramatic increase in the pace of drug development for colorectal cancer which holds promise to further improve curative therapy as part of a multidisciplinary approach in the surgical adjuvant setting. In 2004, surgery remains the primary curative modality for treatment of cancers of the colon or rectum. It has been shown that outcome relates to the experience of the surgeon, particularly for cancer of the rectum. Furthermore, careful histopathologic evaluation of resected tumor specimens, including radial tumor margins and lymph nodes, is important in prognosis and selection of patients for adjuvant therapy. In spite of complete gross tumor removal (ie, "curative resection"), many patients will relapse and die of recurrent colorectal cancer. The risk of relapse following surgery correlates with stage of disease, and ranges from roughly 20% to 30% for stage II disease (Tx, N0) to 50% to 80% for stage III disease (Tx, N+). For patients with rectal cancer it has been shown that local tumor recurrence is highly correlated with both the depth of tumor penetration and the number of regional lymph nodes involved by metastatic disease.[1] There is general consensus that adjuvant therapy is indicated for most patients with stage III cancer of the colon or rectum and stage II cancer of the rectum. Opinion is divided whether patients with stage II colon cancer derive sufficient benefit to warrant adjuvant therapy on a routine basis.[ 2,3] The vast majority of tumor relapses occur in sites distant from the primary tumor following surgery for colon cancer. Therefore, the thrust of adjuvant therapy for colon cancer is on systemic treatment aimed at eradicating micrometastatic disease; radiation therapy has a very limited role. On the other hand, local tumor failure in the pelvis is a significant clinical problem for patients with rectal cancer treated with surgery alone, providing a rationale for regional adjuvant radiation therapy. Because distant metastasis is the predominant mode of tumor relapse in patients with rectal cancer who receive aggressive local therapy,[4,5] improved systemic therapy is also a principal focus of rectal cancer adjuvant trials. This paper will first provide a very brief overview of surgical adjuvant therapy for cancer of the colon, and then examine adjuvant therapy for rectal cancer. Emphasis will be placed on the current state-of-the-art and research questions that will be addressed in the next generation of cooperative group clinical trials in the United States. Adjuvant Therapy of Colon Cancer Substantive advances have been made in the surgical adjuvant therapy of colon cancer over the past 15 years. Fluorouracil (5-FU) and levamisole (Ergamisol) was shown by prospectively randomized clinical trials to significantly improve time to tumor recurrence and overall survival for patients with stage III (node-positive, Dukes 'C) colon cancer. The initial results of a North Central Cancer Treatment Group (NCCTG) clinical trial[6] were confirmed by an Intergroup study published in 1990.[7] These results were endorsed by a National Institutes of Health (NIH) Consensus Development Panel, the US Food and Drug Administration (FDA) approved levamisole in combination with 5-FU for patients with stage III colon Page 1 of 5
2 cancer, and this regimen became the standard of care in the United States. Meanwhile, the concept of biochemical modulation of 5-FU by leucovorin was shown to improve the efficacy of palliative chemotherapy for patients with advanced colorectal cancer compared to 5-FU alone.[8,9] Several cooperative group studies then evaluated 5-FU and leucovorin compared to observation following surgery in the adjuvant setting[10,11] and demonstrated an improvement in recurrence- free interval and overall survival. Several cooperative group studies then set out to compare 5-FU plus levamisole to 5-FU plus leucovorin, and combined modulation of 5-FU by both levamisole and leucovorin.[12-14] This set of studies indicated at least equivalent (if not better) results with 5-FU and leucovorin, that the duration of adjuvant therapy could safely be reduced from 12 months to 6 months without decreasing survival benefits, and that the addition of levamisole to 5-FU plus leucovorin increased toxicity without improving outcome. Accordingly, the combination of 5-FU and leucovorin given for approximately 6 months has become the standard approach for surgical adjuvant therapy of colon cancer in the United States. The drugs irinotecan (Camptosar) and oxaliplatin (Eloxatin) have more recently been shown to significantly improve the palliative therapy of advanced colorectal cancer when combined with 5-FU and leucovorin.[15-18] Each of these drugs has now been approved by the FDA for the firstand second-line treatment of metastatic colorectal cancer. The results of ongoing surgical adjuvant trials of irinotecan combined with 5-FU and leucovorin have not yet been reported, but are anticipated in the near future. However, very encouraging results from a large adjuvant study that evaluated oxaliplatin in combination with 5-FU and leucovorin were presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in 2003.[19] This study demonstrated a significant improvement in 3-year disease-free survival for patients with stage II or III colon cancer who received treatment with a FOLFOX regimen compared to patients receiving infusional 5-FU plus leucovorin on the same schedule without oxaliplatin. Follow-up was sufficiently long to reliably conclude that diseasefree survival has been significantly improved with the addition of oxaliplatin, but not long enough to determine the impact on overall 5-year survival. Statistical analyses are under way to determine under what conditions improvement in disease-free survival may be a reliable predictor of survival benefit, and investigators are considering whether disease-free survival may represent clinical benefit in its own right. Nevertheless, the use of oxaliplatin in the surgical adjuvant setting for patients with colon cancer has not been approved by the FDA at the time of this writing. For many years there has been great interest in antiangiogenesis therapy directed at tumor vasculature as a method of cancer treatment. Many preclinical models have shown that this approach had promise, but its value in the treatment of human cancer was not demonstrated until very recently. Bevacizumab (Avastin) is a humanized genetically engineered monoclonal antibody directed against vascular endothelial growth factor. The results of a phase III trial of bevacizumab added to chemotherapy with irinotecan, 5-FU, and leucovorin compared to the same chemotherapy alone for the first-line treatment of patients with metastatic colorectal cancer were reported at the 2003 ASCO meeting.[20] Highly significant improvements in tumor response rates, time to tumor progression, and survival were seen among patients receiving bevacizumab with chemotherapy. The FDA has approved bevacizumab combined with 5-FU-based chemotherapy for the first-line treatment of patients with metastatic colorectal cancer. These very positive results also provide a strong rationale for the study of bevacizumab in the colon cancer surgical adjuvant setting. Another monoclonal antibody with activity in advanced colorectal cancer is cetuximab (Erbitux). This antibody binds the epidermal growth factor receptor. It has been shown to cause tumor regression, especially when combined with irinotecan, in patients with metastatic colon cancer previously treated with chemotherapy.[ 21,22] It is approved by the FDA for second-line treatment of metastatic colorectal cancer, and is also a candidate for investigation in the surgical adjuvant setting. Current and Planned Cooperative Group Trials: Colon Cancer The dramatic benefit seen with the addition of bevacizumab to 5-FU- based chemotherapy in metastatic colorectal cancer serves as the basis for two colon cancer adjuvant therapy clinical trials. The first will be conducted by the National Surgical Adjuvant Breast and Bowel Project (NSABP) in patients with stage II or III colon cancer. The plan is that all patients will receive chemotherapy with oxaliplatin, infusional 5-FU, and leucovorin (specifically, the mfolfox6 treatment schedule) for 6 months. Half of the patients will be randomized to receive bevacizumab in addition for a period of 1 year. The second trial will be coordinated by the Eastern Cooperative Oncology Group (ECOG) on behalf of the GI Intergroup. It will focus on high-risk stage II patients (identified by molecular markers expressed on the resected tumor). It is planned that all patients will receive 6 months of mfolfox6, and half of the patients will also receive bevacizumab for a period of 1 year. Analysis of numerous clinical trials of chemotherapy for metastatic colorectal cancer has indicated that the longest survival has been seen in patients who were able to receive multiple Page 2 of 5
3 effective agents as first-line or "salvage" therapy. Although this type of analysis is subject to selection bias, it raises the possibility that improved long-term survival might be seen in the adjuvant setting if multiple effective drugs were used "up front." The NCCTG will coordinate an Intergroup clinical trial that will evaluate this concept in patients with stage III colon cancer. Patients will be randomly assigned to receive treatment with oxaliplatin plus infusional 5-FU plus leucovorin (mfolfox6), irinotecan plus infusional 5-FU plus leucovorin (FOLFIRI), or mfolfox6 followed by FOLFIRI. Treatment duration will be 6 months in each of the treatment arms. As can be seen, this trial will also afford the opportunity to directly compare irinotecan and oxaliplatin when combined with infusional 5-FU plus leucovorin. Adjuvant Therapy of Rectal Cancer The same NIH Consensus Development Panel that recommended 5-FU and levamisole as adjuvant therapy for stage III colon cancer in 1990 also recommended postoperative combined- modality therapy with chemotherapy and irradiation for patients with stage II or III rectal cancer. These recommendations were based largely on the results of randomized clinical trials performed by the Gastrointestinal Tumor Study Group[23] and the NCCTG.[24] Improved local tumor control in the pelvis and improved survival were seen when both modalities were used compared to surgery or surgery followed by radiation therapy. The NSABP subsequently reported that chemotherapy could improve disease-free survival,[25] and that the addition of radiation therapy to chemotherapy could significantly decrease local tumor recurrence.[26] An Intergroup trial reported in 1994 demonstrated that the prolonged (continuous) infusion of 5-FU during radiation decreased local tumor failure and improved survival compared to bolus 5-FU during radiation as a component of sequential combinedmodality postoperative adjuvant therapy.[ 4] This strategy was adopted by many oncologists as a standard approach to adjuvant therapy of rectal cancer in the United States. The improvements seen with adjuvant therapy of colon cancer using 5-FU modulated by either levamisole or leucovorin were tested in an Intergroup trial compared to the use of single-agent 5-FU as the systemic therapy.[ 5] Interestingly, there were no significant differences between single- agent 5-FU and 5-FU modulated by leucovorin, levamisole, or the combination when used as a component of postoperative combined-modality therapy for rectal cancer. An Intergroup clinical trial coordinated by the Southwest Oncology Group that further evaluated the continuous 5-FU infusion theme was reported at the 2003 ASCO annual meeting.[27] This study evaluated continuous infusion 5-FU given during radiation only; infusion 5-FU before, during, and after radiation; and a regimen using bolus 5-FU modulated by levamisole and leucovorin without continuous infusion 5-FU at all. There was no significant difference in outcome between these approaches. Because previous studies failed to show any advantage in adding levamisole to leucovorin-modulated 5-FU in the adjuvant therapy of colon cancer or rectal cancer, levamisole cannot be recommended. With the exception of levamisole, any of the regimens in this study would be reasonable as postoperative adjuvant therapy for patients with rectal cancer. It should be noted that there may be advantages in avoiding the need for a central venous catheter and ambulatory infusion pump necessary for the administration of continuous infusion 5-FU by selecting the 5-FU plus leucovorin chemotherapy regimen. Preoperative (neoadjuvant) therapy has been preferred over postoperative adjuvant therapy for rectal cancer in Europe for some period of time. Studies in the United States have also suggested less acute and chronic gastrointestinal toxicity from preoperative radiation therapy,[28] and practice patterns are shifting toward preoperative radiation therapy in this country. A prospectively randomized clinical trial comparing preoperative vs postoperative combined-modality therapy was reported at the 2003 meeting of the American Society of Therapeutic Radiology by the German Rectal Cancer Group.[29] This study demonstrated a significant reduction in local tumor relapse and less toxicity from preoperative combinedmodality therapy as compared to similar treatment given postoperatively. These data provide a strong rationale to consider sequencing radiation prior to surgery for operable T3 or T4 rectal cancer. Current and Planned Cooperative Group Trials: Rectal Cancer Members of the North American cooperative groups investigating adjuvant therapy for rectal cancer have designed two complementary clinical trials to address several critical questions. The first is an Intergroup study coordinated by ECOG. It will examine whether the addition of either oxaliplatin or irinotecan to the 5-FU plus leucovorin combination (using FOLFOX or FOLFIRI) will be more effective than 5-FU plus leucovorin in decreasing the rate of distant metastasis, thereby improving long-term survival. This study will allow radiation therapy with concomitant fluorinated pyrimidine chemotherapy to be given either preoperatively or postoperatively at the discretion of the patient and physician. The second study is an NSABP study that will evaluate oral capecitabine (Xeloda) as an enhancer of radiation therapy in the preoperative setting. The goal is to improve the tolerability and effectiveness of combined- modality therapy in preventing local tumor failure by using a drug preferentially activated in tumor tissue. Patients participating in this trial will also be eligible to Page 3 of 5
4 participate in the ECOG trial that is addressing systemic tumor failure as described above. Summary and Conclusions The therapy of colorectal cancer has advanced dramatically since The long-term survival rates of patients with primary colon cancer have unequivocally improved with the use of effective surgical adjuvant chemotherapy. The incorporation of oxaliplatin, irinotecan, and the monoclonal antibodies bevacizumab and cetuximab into surgical adjuvant regimens holds the prospect for further advances in the next few years. From a longer- range perspective, one can realistically anticipate additional new agents emanating from the pharmaceutical industry pipeline that will further add to our armamentarium. Local tumor recurrences, which can produce devastating symptoms for patients with primary rectal cancer, have been greatly reduced with the use of combined radiation therapy and chemotherapy when added to complete surgical resection. There is evidence that preoperative combinedmodality therapy is better tolerated and more effective in providing local tumor control compared to postoperative adjuvant therapy. Hopefully, incorporation of new drugs shown to be effective in metastatic colorectal cancer will also decrease the problem of distant metastasis when used in the surgical adjuvant setting for patients with rectal cancer. Finally, it is important never to be satisfied with the status quo. Correlative science studies aimed at identifying prognostic and predictive markers must be undertaken to facilitate selection of patients that truly need surgical adjuvant therapy, and specific treatments best suited to individual patients. As in the past, future progress will depend on well-conducted clinical trials supported by community physicians and patients alike. We presently have the good fortune of a number of promising avenues to investigate. Disclosures: The author is on the scientific advisory boards of Sanofi Pharmaceuticals, Novartis Pharmaceuticals, and Genentech. References: 1. Gunderson LL, Sargent DS, Tepper J, et al: Impact of TN stage and treatment on survival and relapse in adjuvant rectal cancer pooled analysis (abstract 1008). Proc Am Soc Clin Oncol 22:251, Mamounas E, Wieand S, Wolmark N, et al: Comparative efficacy of adjuvant chemotherapy in patients with Dukes B versus Dukes C colon cancer: Results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 17(5): , Buyse M, Piedbois P: Should Dukes B patients receive adjuvant therapy? A statistical perspective. Semin Oncol 28(1 suppl 1):20-24, O Connell MJ, Martenson JA, Wieand HS, et al: Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331: , Tepper JE, O Connell MJ, Niedzwiecki D, et al: Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control: Final report of intergroup J Clin Oncol 20(7): , Laurie JA, Moertel CG, Fleming TR, et al: Surgical adjuvant therapy of large-bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 7(10): , Moertel CG, Fleming TR, MacDonald JS, et al: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med 122: , Poon MA, O Connell MJ, Wieand HS, et al: Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9: , Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 10: , O Connell MJ, Mailliard JA, Kahn MJ, et al: Controlled trial of fluorouracil and lowdose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15(1): , International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators: Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 345: , Wolmark N, Rockette H, Fisher B, et al: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 11(10): , Haller DG, Catalano PJ, Macdonald JS, et al: Fluorouracil (FU), leucovorin (LV) and levamisole Page 4 of 5
5 (LEV) adjuvant therapy for colon cancer: Five-year final report of INT Proc Am Soc Clin Oncol 17:256a, O Connell MJ, Laurie JA, Kahn M, et al: Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16(1): , Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343(13): , Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355(9209): , degramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: , Goldberg R, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, degramont A, Banzi M, Navarro M, et al: Oxaliplatin 5/FU/LV in adjuvant colon cancer: Results of the international randomized mosaic trial (abstract 1015). Proc Am Soc Clin Oncol 22:253, Hurwitz H, Fehrenbacher L, Cartwright T, et al: Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC). Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC (abstract 3646). Proc Am Soc Clin Oncol 22: Saltz LB, Meropol NJ, Loehrer PJ Sr, et al: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22: , Cunningham D, Humblet Y, Siena S, et al: Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC) (abstract 1012). Proc Am Soc Clin Oncol 22:252, Gastrointestinal Tumor Study Group: Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med 312: , Krook JE, Moertel CG, Gunderson LL, et al: Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 324(11): , Fisher B, Wolmark N, Rockette H, et al: Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: Results from NSABP protocol R-01. J Natl Cancer Inst 80(1):21-29, Wolmark N, Wieand HS, Hyams DM, et al: Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst 92(5): , Smalley SR, Benedetti J, Williamson S, et al: Intergroup 0114 phase III trial of 5-FU based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer (abstract 1006). Proc Am Soc Clin Oncol 22:251, Minsky BD, Cohen AM, Kemeny N, et al: Combined modality therapy of rectal cancer: Decreased acute toxicity with the preoperative approach. J Clin Oncol 10(8): , R. Sauer for the German Rectal Cancer Group: Adjuvant versus neoadjuvant combined modality treatment for locally advanced rectal cancer: First results of the German Rectal Cancer Study (CAO/ARO/AIO-94) (abstract 2). Int J Radiat Oncol Biol Phys 57(2 suppl):s124, Source URL: Links: [1] [2] Page 5 of 5
Adjuvant therapies for large bowel cancer Wasantha Rathnayake, MD
LEADING ARTICLE Adjuvant therapies for large bowel cancer Wasantha Rathnayake, MD Consultant Clinical Oncologist, National Cancer Institute, Maharagama, Sri Lanka. Key words: Large bowel; Cancer; Adjuvant
More information/m 2 Oxaliplatin 85 1 Q2W 1-3 Leucovorin Q2W 5-FU Q2W 5-FU Q2W
癌症診療指引33 Adjuvant therapy of colon cancer mfolfox6 Oxaliplatin 85 1 Q2W 1-3 FOLFOX4 Oxaliplatin 85 1 Q2W 9 Leucovorin 200 1-2 Q2W 5-FU 400 1-2 Q2W 5-FU 600 1-2 Q2W FLOX Oxaliplatin 85 1,15,29 Q8W 4 Leucovorin
More informationRadiation Therapy for Resectable Colon Cancer
Review Article [1] February 01, 2006 By Brian G. Czito, MD [2], Johanna C. Bendell, MD [3], and Christopher G. Willett, MD [4] Colon cancer is a major public health problem. The primary treatment is resection.
More informationDisclosures. Colorectal Cancer Update GAFP November Risk Assessment. Colon and Rectal Cancer The Challenge. Issues in Colon and Rectal Cancer
Disclosures Colorectal Cancer Update GAFP November 2006 Robert C. Hermann, MD Georgia Center for Oncology Research and Education Northwest Georgia Oncology Centers, PC WellStar Health System Marietta,
More information療指引 34 Adjuvant Therapy of Colon Cancer
療指引 34 Adjuvant Therapy of Colon Cancer mfolfox6 Oxaliplatin 85 1 Q2W 1~3, 10 FLOX Oxaliplatin 85 1,15,29 Q8W 4 Leucovorin 500 1,8,15,22,29,35 Q8W 5-FU 500 1,8,15,22,29,35 Q8W Capecitabine Capecitabine
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GASTROINTESTINAL RECTAL CANCER GI Site Group Rectal Cancer Authors: Dr. Jennifer Knox, Dr. Mairead McNamara 1. INTRODUCTION 3 2. SCREENING AND
More informationAdjuvant therapy in colon cancer: which treatment in 2005?
Annals of Oncology 16 (Supplement 4): iv69 iv73, 2005 doi:10.1093/annonc/mdi911 Adjuvant therapy in colon cancer: which treatment in 2005? F. Di Costanzo* & L. Doni Medical Oncology Unit, Department of
More informationChemotherapy of colon cancers
Chemotherapy of colon cancers Stage distribution Stage I : 15% T 1,2 NO Stage IV: 20 25% M+ Stage II : 20 30% T3,4 NO Stage III N+: 30 40% clinical stages I, II, or III colon cancer are at risk for having
More informationNorthwestern University, Division of Hematology/Oncology, Chicago, Illinois, USA. Key Words. Colon cancer Stage II Adjuvant chemotherapy
The Oncologist Dialogues in Oncology Adjuvant Therapy in Stage II Colon Cancer: Current Approaches LISA BADDI, AL BENSON III Northwestern University, Division of Hematology/Oncology, Chicago, Illinois,
More informationManagement of Advanced Colorectal Cancer in Older Patients
Review Article [1] April 15, 2005 By Stuart M. Lichtman, MD, FACP [2] Many elderly individuals have substantial life expectancy, even in the setting of significant illness. There is evidence to indicate
More informationCOLORECTAL CANCER 44
COLORECTAL CANCER 44 Colorectal Cancer Highlights from the 2009 Annual Meeting of the American Society of Clinical Oncology Edited by Stuart M. Lichtman, MD Memorial Sloan-Kettering Cancer Center Commack,
More informationCase Conference. Craig Morgenthal Department of Surgery Long Island College Hospital
Case Conference Craig Morgenthal Department of Surgery Long Island College Hospital Neoadjuvant versus Adjuvant Radiation Therapy in Rectal Carcinoma Epidemiology American Cancer Society statistics for
More informationComparative Efficacy of Adjuvant Chemotherapy in Patients With Dukes B Versus Dukes C Colon Cancer: Results From
Comparative Efficacy of Adjuvant Chemotherapy in Patients With Dukes B Versus Dukes C Colon Cancer: Results From Four National Surgical Adjuvant Breast and Bowel Project Adjuvant Studies (C-01, C-02, C-03,
More informationEfficacy and Toxicity of Adjuvant Chemotherapy in Elderly Patients with Colon Carcinoma
1931 Efficacy and Toxicity of Adjuvant Chemotherapy in Elderly Patients with Colon Carcinoma A 10-Year Experience of the Geisinger Medical Center Farid Fata, M.D. 1 Ayoub Mirza, M.D. 2 G. Craig Wood, M.S.
More informationUpdate on Chemotherapy for Advanced Colorectal Cancer
Review Article [1] March 02, 2001 By Daniel G. Haller, MD [2] Efforts to improve the length and quality of life, as well as to expand treatment options, for patients with metastatic colorectal cancer have
More informationFactors associated with delayed time to adjuvant chemotherapy in stage iii colon cancer
Curr Oncol, Vol. 21, pp. 181-186 doi: http://dx.doi.org/10.3747/co.21.1963 DELAYED TIME TO ADJUVANT CHEMOTHERAPY ORIGINAL ARTICLE Factors associated with delayed time to adjuvant chemotherapy in stage
More informationEvaluation of the Efficacy of Modified De Gramont and Modified FOLFOX4 Regimens for Adjuvant Therapy of Locally Advanced Rectal Cancer
Efficacy of Modified De Gramont and FOLFOX4 Regimens for Locally Advanced Rectal Cancer RESEARCH COMMUNICATION Evaluation of the Efficacy of Modified De Gramont and Modified FOLFOX4 Regimens for Adjuvant
More information大腸直腸癌 抗癌藥物治療指引 討論日期 團隊討論 : 105 年 10 月 19 日 三院討論 : 105 年 12 月 7 日 團隊確認 : 106 年 1 月 25 日 核備日期 : 106 年 4 月 18 日
大腸直腸癌 抗癌藥物治療指 討論日期 團隊討論 : 05 年 0 月 9 日 三院討論 : 05 年 2 月 7 日 團隊確認 : 06 年 月 25 日 核備日期 : 06 年 4 月 8 日 Adjuvant Therapy of Colon Cancer mfolfox6 參考文獻 -3 Oxaliplatin 85 Q2W 2 Leucovorin 400 Q2W 2 5-FU 400 Q2W
More informationWeekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after colorectal cancer resection
Original article Annals of Oncology 15: 568 573, 2004 DOI: 10.1093/annonc/mdh134 Weekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after
More informationAdjuvant Chemotherapy for Rectal Cancer: Are we making progress?
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones
More informationChemotherapy for resectable liver mets: Options and Issues. Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA
Chemotherapy for resectable liver mets: Options and Issues Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA Chemotherapy regimens in 1 st line mcrc Standard FOLFOX-Bev FOLFIRI-Bev
More informationRetrospective analysis of the effect of CAPOX and mfolfox6 dose intensity on survival in colorectal patients in the adjuvant setting
ORIGINAL ARTICLE CAPOX AND mfolfox6 DOSE INTENSITY AND CLINICAL OUTCOMES IN STAGE III CRC, Mamo et al. Retrospective analysis of the effect of CAPOX and mfolfox6 dose intensity on survival in colorectal
More informationDisclosures. Clinical and molecular features to guide adjuvant therapy. Personalized Medicine - Decision Tools -
Disclosures Clinical and molecular features to guide adjuvant therapy Daniel Sargent Professor of Biostatistics & Oncology Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis
More informationStage III Colon Cancer Susquehanna Cancer Center Warren L Robinson, MD, FACP May 9, 2007
Stage III Colon Cancer Susquehanna Cancer Center 1997-21 Warren L Robinson, MD, FACP May 9, 27 Stage III Colon Cancer Susquehanna Cancer Center 1997-21 Colorectal cancer is the third most common cancer
More informationState of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan
State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan Consultant GI Medical Oncologist National Cancer Centre Singapore Clinician Scientist, Genome Institute of Singapore OS (%) Overall survival
More informationRectal Cancer. GI Practice Guideline
Rectal Cancer GI Practice Guideline Dr. Brian Dingle MSc, MD, FRCPC Dr. Francisco Perera MD, FRCPC (Radiation Oncologist) Dr. Jay Engel MD, FRCPC (Surgical Oncologist) Approval Date: 2006 This guideline
More informationPharmacologyonline 1: (2010)
THE EFFECT OF USING COMBINATION CHEMOTHERAPY IN COLORECTAL CANCER IN INDIA: A SINGLE INSTITUTE SURVEY Adiga Sachidananda*, Meena Kumari K**, Bairy KL***, Mohan Babu A**, Vadiraja BM+, Vidyasagar MS++ *Associate
More informationColorectal Cancer Therapy and Associated Toxicity
Colorectal Cancer Therapy and Associated Toxicity Mountain States Cancer Conference November 6, 2010 Colin D. Weekes, M.D., Ph.D Assistant Professor University of Colorado GI Cancers Are Common 2009 Estimated
More informationIs it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS
Is it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS Survival Rates of by Stage of Adenocarcinoma of the Colon Liver Resection New Perspective Colorectal cancer liver
More informationReview. A. Di Leo 1 *, M. Buyse 2 & H. Bleiberg 1. Introduction. Design and main results of the trials
Review Annals of Oncology 15: 545 549, 2004 DOI: 10.1093/annonc/mdh127 Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical
More informationTherapy for Metastatic Colorectal Cancer
Therapy for Metastatic Colorectal Cancer Richard M. Goldberg Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA Learning Objectives Key
More informationThe International Duration Evaluation of Adjuvant Chemotherapy study: implications for clinical practice
Editorial The International Duration Evaluation of Adjuvant Chemotherapy study: implications for clinical practice Marwan Fakih Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive
More informationEfficiency and tolerability of 5- fluorouracil-based adjuvant chemotherapy in elderly patients with colorectal carcinoma
Turkish Journal of Cancer Volume 34, No.4, 2004 139 Efficiency and tolerability of 5- fluorouracil-based adjuvant chemotherapy in elderly patients with colorectal carcinoma LHAN ÖZTOP 1, ARZU YAREN 1,
More informationCarcinoma del retto: Highlights
Carcinoma del retto: Highlights Stefano Cordio Struttura Complessa di Oncologia Medica ARNAS Garibaldi Catania Roma 17 Febbraio 2018 Disclosures Advisory Committee, research funding and speakers bureau
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationJY Douillard MD, PhD Professor of Medical Oncology
Colorectal Cancer ESMO Preceptorship Program Prague May 22-23rd 2014 Review of the ESMO Consensus Conference on metastatic colo-rectal cancer Basic strategy and groups (RASwt/mut, BRAF mut) JY Douillard
More informationCetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer
Cetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer Cetuximab with Chemotherapy (CT) as First-Line Treatment for Metastatic Colorectal Cancer (mcrc): Analysis of
More informationAssociation of Canada. Learning about. Colorectal Cancer. A Personalized Treatment Guide for Patients
Colorectal Cancer Association of Canada Learning about Colorectal Cancer A Personalized Treatment Guide for Patients Avastin is a trademark of Genentech, Inc., Used under licence. Camptosar is a registered
More informationThe efficacy of bevacizumab in Chinese patients with metastatic colorectal cancer and its effect in different line setting*
Chinese-German J Clin Oncol DOI 10.1007/s10330-014-1295-2 April 2014, Vol. 13, No. 4, P169 P173 The efficacy of bevacizumab in Chinese patients with metastatic colorectal cancer and its effect in different
More informationSurgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
More informationTreatment of Locally Advanced Rectal Cancer: Current Concepts
Treatment of Locally Advanced Rectal Cancer: Current Concepts James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS Case Presentation
More informationAdjuvant chemotherapy outcomes in patients over 65 years with early stage colorectal carcinoma
JBUON 2014; 19(4): 906-912 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Adjuvant chemotherapy outcomes in patients over 65 years with early
More informationAdvances in Chemotherapy of Colorectal Cancer
Advances in Chemotherapy of Colorectal Cancer Richard M. Goldberg Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Disease Settings Adjuvant Therapy MOSAIC, FOLFOX Andre
More informationADJUVANT CHEMOTHERAPY FOR RECTAL CANCER
ESMO Preceptorship Programme Colorectal Cancer Barcelona November, 25-26, 2016 ADJUVANT CHEMOTHERAPY FOR RECTAL CANCER Andrés Cervantes Professor of Medicine OLD APPROACH TO RECTAL CANCER Surgical resection
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
of the clinical trial data for this outcome. Therefore, perc considered that the cost-effectiveness of cetuximab plus FOLFIRI would be at the higher end of the EGP s range of best estimates. Therefore,
More informationDevelopment of Conventional Chemotherapy in mcrc BSC vs. Chemo, Biochemical modulation, Oral fluoropyrimidines, Developmentof combination chemotherapy
ESMO Preceptorship Colorectal Cancer Colorectal ESMO Cancer Preceptorship Valencia May Program 20-21st 2016 Prague May 22-23rd 2014 Development of Conventional Chemotherapy in mcrc BSC vs. Chemo, Biochemical
More informationAdjuvant Chemotherapy for Patients with Resected Dukes C and High-risk B2 Colon Cancer with Fluorouracil and Levamisole
733 Adjuvant Chemotherapy for Patients with Resected Dukes C and High-risk B2 Colon Cancer with Fluorouracil and Levamisole E Au,*FAMS, M Med (Int Med), MRCP, P T Ang,**FAMS, FACP, FRCP (Edin), F Seow-Choen,***FAMS,
More informationPresent Status and Perspectives of Colorectal Cancer in Asia: Colorectal Cancer Working Group Report in 30th Asia-Pacific Cancer Conference
Present Status and Perspectives of Colorectal Cancer in Asia: Colorectal Cancer Working Group Report in 30th Asia-Pacific Cancer Conference Jpn J Clin Oncol 2010;40(Supplement 1)i38 i43 doi:10.1093/jjco/hyq125
More informationPharmacy Management Drug Policy
11/13, 10/12, 11/11, 1, 6/10, Page 1 of 5 DESCRIPTION: Cetuximab is a recombinant humanized monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor
More informationErbitux. Erbitux (cetuximab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.84 Subject: Erbitux Page: 1 of 6 Last Review Date: December 2, 2016 Erbitux Description Erbitux (cetuximab)
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,500 108,000 1.7 M Open access books available International authors and editors Downloads Our
More informationJonathan Dickinson, LCL Xeloda
Xeloda A blockbuster in the making Jonathan Dickinson, LCL Xeloda Xeloda unique tumor-activated mechanism Delivering more cancer-killing agent straight into cancer Highly effective comparable efficacy
More informationANTICANCER RESEARCH 26: (2006)
Clinical Impact of Adjuvant Chemotherapy on Patients with Stage III Colorectal Cancer: l-lv/5fu Chemotherapy as a Modified RPMI Regimen is an Independent Prognostic Factor for Survival TSUKASA HOTTA, KATSUNARI
More informationADJUVANT CHEMOTHERAPY...
Colorectal Pathway Board: Non-Surgical Oncology Guidelines October 2015 Organization» Table of Contents ADJUVANT CHEMOTHERAPY... 2 DUKES C/ TNM STAGE 3... 2 DUKES B/ TNM STAGE 2... 3 LOCALLY ADVANCED
More informationAppendix E - Summary form Oxaliplatin and capecitabine for the adjuvant treatment of colon cancer table of consultee comments
Oxaliplatin and capecitabine for the adjuvant treatment of colon cancer table of consultee comments Section Consultees Comments Action Objective Roche RCP RCP As far as capecitabine is concerned, the objective
More informationAdjuvant treatment Colon Cancer
ESMO Preceptorship Colorectal Cancer, October 2016 Singapore Adjuvant treatment Colon Cancer Claus-Henning Köhne University Clinic for Onkology und Haematology Oldenburg, Germany Aim of the lecture Adjuvant
More informationKaoru Takeshima, Kazuo Yamafuji, Atsunori Asami, Hideo Baba, Nobuhiko Okamoto, Hidena Takahashi, Chisato Takagi, and Kiyoshi Kubochi
Case Reports in Surgery Volume 2016, Article ID 4548798, 5 pages http://dx.doi.org/10.1155/2016/4548798 Case Report Successful Resection of Isolated Para-Aortic Lymph Node Recurrence from Advanced Sigmoid
More informationIl paziente anziano con malattia oncologica avanzata: il tumore del colon-retto
Milano 05.10.2018 Il paziente anziano con malattia oncologica avanzata: il tumore del colon-retto Salvatore Corallo U.O.C. Oncologia Medica IRCCS Istituto Nazionale dei Tumori Milano CRC in elderly patients
More informationS u p p o r t e d b y a n i n d e p e n d e n t E d u c a t i o n a l G r a n t f r o m B a y e r
EXPERTS KNOWLEDGE SHARE with Prof. Köhne, Dr. Modest and Dr. Vecchione Madrid (Spain) Sunday September 10 th 2017 S u p p o r t e d b y a n i n d e p e n d e n t E d u c a t i o n a l G r a n t f r o m
More information2/20/14& Medical Management of Colon and Rectal Cancer: An Overview. Outline / Learning Objectives. How common is colon cancer?
Medical Management of Colon and Rectal Cancer: An Overview Jonathan Grim, MD, PhD VA Puget Sound Health Care System Fred Hutchinson Cancer Research Center UW Medicine Outline / Learning Objectives Epidemiology
More informationJY Douillard MD, PhD Professor of Medical Oncology
ESMO Preceptorship Colorectal Cancer Colorectal ESMO Cancer Preceptorship Vienna 26-27 Program October 2015 Prague May 22-23rd 2014 Review of the ESMO Consensus Conference on metastatic colo-rectal cancer
More informationADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS. Andrés Cervantes. Professor of Medicine
ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS Andrés Cervantes Professor of Medicine 1995 One option Advances in the treatment of mcrc 2000
More informationA clinical study of metastasized rectal cancer treatment: assessing a multimodal approach
Med Oncol (2014) 31:839 DOI 10.1007/s12032-014-0839-1 ORIGINAL PAPER A clinical study of metastasized rectal cancer treatment: assessing a multimodal approach Michaela Jung Annica Holmqvist Xiao-Feng Sun
More informationAdjuvant Chemotherapy for Stage II Colon Cancer
March 01, 2008 By Scott Kopetz, MD [1], Daniela Freitas, MD [2], Aknar F. C. Calabrich, MD [3], and Paulo M. Hoff, MD, FACP [4] Adjuvant therapy is defined as any treatment administered after surgical
More informationCHEMOTHERAPY FOR COLON CANCER OUTLINE OF TODAY S TALK. Colon Cancer Epidemiology 11/6/2012 GATRA/GCCR FALL CONFERENCE NOVEMBER 14 16, 2012
CHEMOTHERAPY FOR COLON CANCER JONATHAN C. BENDER,MD MEDICAL DIRECTOR OF PIEDMONT FAYETTE CANCER CENTER OUTLINE OF TODAY S TALK 1. Overview of Colon Cancer in the US 2. Colon Cancer staging and risks of
More informationOVERALL CLINICAL BENEFIT
cetuximab plus FOLFIRI to convert unresectable liver metastatses to resectable, perc confirmed that neither the FIRE-3 study nor the CRYSTAL study were designed to assess resectability and, in the absence
More informationDoes it matter which chemotherapy regimen you partner with the biologic agents?
Does it matter which chemotherapy regimen you partner with the biologic agents? Yes, it does matter! Axel Grothey Disclosures Research Funding to MAYO Clinic Genentech Bayer Eisai Pfizer Imclone Potential
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationWhat s New in Colon Cancer? Therapy over the last decade
What s New in Colon Cancer? 9/19/2014 Michael McNamara, MD Therapy over the last decade Cytotoxic chemotherapy - 5FU ( Mayo, Roswell, Infusional) - Xeloda (01 ) - Oxaliplatin (02 ) - Irinotecan (96 ) Anti-
More informationHas Real Progress Been Made in Chemotherapy for Colon Cancer?
Series Editor: Melvin Schapiro, M.D. Has Real Progress Been Made in Chemotherapy for Colon Cancer? Avrum Z. Bluming The introduction of capecitabine, irinotecan, oxaliplatin, and the anti-angiogenesis
More informationNew Options in Metastatic Colorectal Cancer. Jeffrey A. Bubis, DO, FACOI, FACP Fleming Island Baptist South Palatka
New Options in Metastatic Colorectal Cancer Jeffrey A. Bubis, DO, FACOI, FACP Fleming Island Baptist South Palatka 4 th most frequently diagnosed CA in the US 2 nd leading cause of CA death in the US Incidence
More informationIs adjuvant radiotherapy warranted in resected pt1-2 node-positive rectal cancer?
Peng et al. Radiation Oncology 2013, 8:290 RESEARCH Open Access Is adjuvant radiotherapy warranted in resected pt1-2 node-positive rectal cancer? Junjie Peng 1,2, Xinxiang Li 1,2, Ying Ding 3, Debing Shi
More informationVectibix. Vectibix (panitumumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.85 Subject: Vectibix Page: 1 of 5 Last Review Date: December 2, 2016 Vectibix Description Vectibix
More informationLong Term Outcomes of Preoperative versus
RESEARCH ARTICLE Long Term Outcomes of Preoperative versus Postoperative Concurrent Chemoradiation for Locally Advanced Rectal Cancer: Experience from Ramathibodi Medical School in Thailand Pichayada Darunikorn
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationColon Cancer Molecular Target Agents
Colon Cancer Molecular Target Agents Ci Caio Max SR S. Rocha Lima, M.D. MD Professor of Medicine CDi CoDiretor Cl Colorectal tlheptobiliary, Pancreatic SDG, and Phase I Unit University of Miami & Silvester
More informationAdjuvant/neoadjuvant systemic treatment of colorectal cancer
5th ESO-ESMO Eastern Europe and Balkan Region Masterclass in Medical Oncology Belgrade, June 19 th 2018 Adjuvant/neoadjuvant systemic treatment of colorectal cancer Carlotta Antoniotti Polo Oncologico
More informationIs There a New Standard of Care for Adjuvant Therapy in Colon Cancer? When is 3 Months Enough?
Is There a New Standard of Care for Adjuvant Therapy in Colon Cancer? When is 3 Months Enough? Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA 1 Disclosure Ad Board: Genentech Honorarium:
More informationAdjuvant and neoadjuvant chemotherapy for rectal cancer: Expensive but little gain
Adjuvant and neoadjuvant chemotherapy for rectal cancer: Expensive but little gain Outline The problem Adjuvant therapy Neoadjuvant therapy Options Conclusion The problem 30 years ago: Local recurrence
More informationRoche setting the standards of cancer care Oncology Event for Investors, June 19
Roche setting the standards of cancer care Oncology Event for Investors, June 19 Kapil Dhingra, VP Medical Science Developing a drug to the standard of care Superior clinical benefit, resources and time
More informationDescription of Procedure or Service. Policy. Benefits Application
Corporate Medical Policy KRAS, NRAS, BRAF Mutation Analysis and Related File Name: Origination: Last CAP Review: Next CAP Review: Last Review: kras_nras_braf_mutation_analysis_and_related_treatment_in_metastatic_colorectal_cancer
More informationAdjuvant chemotherapy for high-risk stage II and stage III colon cancer: timing of initiation and optimal duration
JBUON 2018; 23(3): 568-573 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com REVIEW ARTICLE Adjuvant chemotherapy for high-risk stage II and stage III colon cancer:
More informationColorectal cancer (CRC) is the fourth most common REVIEW. Advances in Chemotherapy for Colorectal Cancer. Staging and Prognostic Factors
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:808 821 REVIEW Advances in Chemotherapy for Colorectal Cancer DIRK M. BERNOLD* and FRANK A. SINICROPE*, *Division of Oncology, Division of Gastroenterology
More informationtrial update clinical
clinical trial update by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UMPC Cancer Centers In order to provide the most up-to-date and efficacious care to their patients, oncologists must
More informationAdjuvant Treatment of Colorectal Cancer
Adjuvant Treatment of Colorectal Cancer Adjuvant Treatment of Colorectal Cancer Brian M. Wolpin, MD; Jeffrey A. Meyerhardt, MD, MPH; Harvey J. Mamon, MD, PhD; Robert J. Mayer, MD Dr. Wolpin is Instructor
More informationOxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
original article Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer Thierry André, M.D., Corrado Boni, M.D., Lamia Mounedji-Boudiaf, M.D., Matilde Navarro, M.D., Josep Tabernero,
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
More informationBevacizumab is currently licensed for the following indication relevant for this NICE review:
Roche Executive Summary Context Bevacizumab (Avastin) is a humanized (93% human) murine monoclonal antibody which binds to and neutralizes VEGF, a powerful pro-angiogenic glycoprotein produced by both
More informationManagement of early rectal cancer: Any role for adjuvant chemotherapy
Management of early rectal cancer: Any role for adjuvant chemotherapy Andrés Cervantes Professor of Medicine CURRENTS CONCEPTS IN RECTAL CANCER DIAGNOSIS AND THERAPY TME surgery Optimal staging by MRI
More informationTerapia neoadyuvante en cáncer de recto Estado del arte Mauricio Lema Medina MD Clínica de Oncología Astorga / Clínica SOMA - Medellín, Colombia
Terapia neoadyuvante en cáncer de recto Estado del arte Mauricio Lema Medina MD Clínica de Oncología Astorga / Clínica SOMA - Medellín, Colombia Temario Generalidades Adyuvancia en colon y recto FU / Capecitabina
More informationclinical practice guidelines
Annals of Oncology 21 (Supplement 5): v93 v97, 2010 doi:10.1093/annonc/mdq222 Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment E. Van Cutsem 1, B. Nordlinger 2 & A. Cervantes
More informationCetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS)
Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS) C Bokemeyer, E Staroslawska, A Makhson, I Bondarenko, JT Hartmann,
More informationCytotoxic Chemotherapy for Advanced Colorectal Cancer
Review Article [1] November 02, 2005 By Scott Kopetz, MD [2] and Paulo M. Hoff, MD, FACP [3] Several developments in the past few years have incrementally progressed the field and provided additional insights
More informationADJUVANT AND NEOADJUVANT MANAGEMENT OF COLORECTAL CANCER
gastrointestinal tract and abdomen ADJUVANT AND NEOADJUVANT MANAGEMENT OF COLORECTAL CANCER Christina E. Bailey, MD, MSCI, Eduardo Vilar, MD, PhD, and Y. Nancy You, MD, MHSc In 2013, colorectal cancer
More informationInterval between Surgery and Radiation Therapy Is an Important Prognostic Factor in Treatment of Rectal Cancer
pissn 1598-2998, eissn 2005-9256 Cancer Res Treat. 2012;44(3):187-194 Original Article http://dx.doi.org/10.4143/crt.2012.44.3.187 Open Access Interval between Surgery and Radiation Therapy Is an Important
More informationTreatment strategy of metastatic rectal cancer
35.Schweizerische Koloproktologie-Tagung Treatment strategy of metastatic rectal cancer Gilles Mentha University hospital of Geneva Bern, January 18th, 2014 Colorectal cancer is the third most frequent
More informationreviews Staging, and in the Diagnosis, Managed Care Considerations therapy
reviews therapy Managed Care Considerations in the Diagnosis, Staging, and Treatment of Colorectal Cancer by Johanna Bendell, MD, Director, GI Oncology Research; Associate Director, Drug Development Unit,
More informationHorizon Scanning Technology Briefing. Cetuximab (Erbitux) for metastatic colorectal cancer. National Horizon Scanning Centre.
Horizon Scanning Technology Briefing National Horizon Scanning Centre Cetuximab (Erbitux) for metastatic colorectal cancer December 2006 This technology summary is based on information available at the
More informationIndividual- and trial-level surrogacy in colorectal cancer
Stat Methods Med Res OnlineFirst, published on February 19, 2008 as doi:10.1177/0962280207081864 SMM081864 2008/2/5 page 1 Statistical Methods in Medical Research 2008; 1 9 Individual- and trial-level
More informationOncologic Outcomes of Stage IIIA Colon Cancer for Different Chemotherapeutic Regimens
Original Article Journal of the Korean Society of J Korean Soc Coloproctol 2012;28(5):259-264 http://dx.doi.org/10.3393/jksc.2012.28.5.259 pissn 2093-7822 eissn 2093-7830 Oncologic Outcomes of Stage IIIA
More information